JCEM:超重和肥胖对儿童和青少年肝脏生化指标的影响

2019-10-17 xing.T MedSci原创

由此可见,小儿肝酶正常值随年龄和性别而变化。超重和肥胖与肝脏损害的生化指标升高有关。这些发现强调了预防和治疗儿童和青少年超重和肥胖的必要性。

血浆中肝酶浓度升高通常被用作成人和儿童肝损伤的标志物。目前,尚不清楚肥胖对儿童肝酶浓度的年龄和性别特异性影响。近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,研究人员纳入了来自丹麦儿童和青少年的两个队列的参与者:以人群为基础的队列有1858人,以及超重或肥胖的2155人,年龄在6岁和18岁之间。研究人员分别计算了两个队列中空腹血浆丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、乳酸脱氢酶(LDH)、γ-谷氨酰转移酶(GGT)、胆红素和碱性磷酸酶(ALP)的年龄和性别百分比曲线,并通过质子磁共振波谱法评估了458名参与者的肝脂肪含量。

男孩和女孩的ALT、AST、LDH和ALP浓度均随年龄下降,而女孩的GGT和胆红素在各个年龄段均相当,而男孩则随年龄略有增加。在所有年龄段中,超重或肥胖的儿童和青少年ALT浓度均较高。超重或肥胖男孩的ALT和GGT含量较低。诊断肝脂肪变性(肝脂肪含量>5%)的最佳ALT临界值对于女孩为24.5 U/L(敏感性:55.6%,特异性:84.0%),对于男孩为34.5 U/L(男孩:敏感性:83.7%,特异性:68.2%)。 

由此可见,小儿肝酶正常值随年龄和性别而变化。超重和肥胖与肝脏损害的生化指标升高有关。这些发现强调了预防和治疗儿童和青少年超重和肥胖的必要性。 

原始出处:

Magnus Jung Johansen,et al.The effect of overweight and obesity on liver biochemical markers in children and adolescents.J Clin Endocrinol Metab. 2019.https://doi.org/10.1210/clinem/dgz010

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063278, encodeId=747420632e872, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Nov 28 12:03:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937497, encodeId=1ac8193e49716, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon May 25 08:03:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798337, encodeId=5aba1e98337d8, content=<a href='/topic/show?id=329a68895d0' target=_blank style='color:#2F92EE;'>#生化指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68895, encryptionId=329a68895d0, topicName=生化指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 13 01:03:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777896, encodeId=0f041e778967f, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Nov 17 15:03:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
    2019-11-28 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063278, encodeId=747420632e872, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Nov 28 12:03:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937497, encodeId=1ac8193e49716, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon May 25 08:03:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798337, encodeId=5aba1e98337d8, content=<a href='/topic/show?id=329a68895d0' target=_blank style='color:#2F92EE;'>#生化指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68895, encryptionId=329a68895d0, topicName=生化指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 13 01:03:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777896, encodeId=0f041e778967f, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Nov 17 15:03:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063278, encodeId=747420632e872, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Nov 28 12:03:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937497, encodeId=1ac8193e49716, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon May 25 08:03:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798337, encodeId=5aba1e98337d8, content=<a href='/topic/show?id=329a68895d0' target=_blank style='color:#2F92EE;'>#生化指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68895, encryptionId=329a68895d0, topicName=生化指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 13 01:03:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777896, encodeId=0f041e778967f, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Nov 17 15:03:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063278, encodeId=747420632e872, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Thu Nov 28 12:03:00 CST 2019, time=2019-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937497, encodeId=1ac8193e49716, content=<a href='/topic/show?id=b3252822854' target=_blank style='color:#2F92EE;'>#儿童和青少年#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28228, encryptionId=b3252822854, topicName=儿童和青少年)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon May 25 08:03:00 CST 2020, time=2020-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798337, encodeId=5aba1e98337d8, content=<a href='/topic/show?id=329a68895d0' target=_blank style='color:#2F92EE;'>#生化指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68895, encryptionId=329a68895d0, topicName=生化指标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat Jun 13 01:03:00 CST 2020, time=2020-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777896, encodeId=0f041e778967f, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Sun Nov 17 15:03:00 CST 2019, time=2019-11-17, status=1, ipAttribution=)]
    2019-11-17 smallant2015

相关资讯

Int J Cardiol:利拉鲁肽对非糖尿病超重女性冠状动脉微血管功能障碍患者体重和微血管功能的影响

由此可见,利拉鲁肽治疗导致显著的体重减轻和血压降低,治疗期间没有伴随的症状缓解,并且冠状动脉微血管功能也没有改善。

Hypertension:超重/肥胖的个体血压升高的因素存在性别差异

高血压(BP)是心血管疾病最强的可调节的危险因素。超重/肥胖是高血压的主要危险因素。超重/肥胖患者血压升高的机制途径存在多种性别差异。它们可能导致一种性别特异性的BP血流动力学模式——男性和女性在心脏博出量、总外周阻力(TPR)和心率对较高血压的相对贡献方面可能有所不同。Catriona Syme等人在以人群为基础的36-65岁中年人队列中对上述可能性进行验证。本研究队列共有618个样本,包括28

Diabetes Care:液体代餐,徒有虚名还是实至名归?

适度和持续的减肥已被证明可以减少对降糖药物的需求,并改善超重/肥胖2型糖尿病患者的血糖控制。然而,许多超重/肥胖的2型糖尿病患者在减肥方面却困难重重。

Diabetes Care:益生元预防超重和肥胖妇女的妊娠期糖尿病

由此可见,该研究中表明服用的益生菌不能预防超重和肥胖孕妇的GDM。

Clin Endocrinol:在超重及肥胖人群中,HbA1c及OGTT诊断糖尿病及糖尿病前期可能并不一致

在临床实践中,糖化血红蛋白(HbA1c)作为常用的诊断指标已被美国糖尿病协会(ADA)推荐用于诊断糖尿病及糖尿病前期达数年之久。目前,其与口服葡萄糖耐量试验(OGTT)在诊断糖尿病及糖尿病前期方面的一致性备受关注。那么两者在上述诊断方面的一致性到底如何?近期发表在《临床内分泌学杂志》的一项最新研究为我们带来了新的信息。